** Shares of drugmaker TG Therapeutics TGTX.O rise 15.7% to $34.82
** Co posts Q4 net product revenue of $107.3 million, beating analysts' average estimate of $99.98 million - data compiled by LSEG
** TGTX's Q4 U.S. net product revenue for relapsing multiple sclerosis drug Briumvi came in at $103.6 million
** Co forecasts 2025 total revenue of about $540 million, compared with estimates of $548.2 million
** TGTX rose 71% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。